<html>
<head>
    <title>form8-k.htm</title>
<!-- Licensed to: Edgarprep, Inc.-->
<!-- Document Created using EDGARizerAgent 5.1.5.0 -->
<!-- Copyright 1995 - 2009 Thomson Reuters. All rights reserved. -->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
    <div>
      <hr style="COLOR: black" align="left" noshade size="3" width="100%">
    </div>
    <div>
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
      <hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
    </div>
    <div style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 16pt; FONT-WEIGHT: bold">UNITED
STATES</font></div>
    <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 16pt; FONT-WEIGHT: bold">SECURITIES
AND EXCHANGE COMMISSION</font></div>
    <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 16pt; FONT-WEIGHT: bold">Washington,
D.C.&#160;&#160;20549</font></div>
    <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>
    <div>
      <hr style="COLOR: black" align="center" noshade size="2" width="16%">
    </div>
    <div style="TEXT-INDENT: 0pt; DISPLAY: block"><br></div>
    <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 16pt; FONT-WEIGHT: bold">Form
8-K</font></div>
    <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
      <hr style="COLOR: black" align="center" noshade size="2" width="16%">&#160;</div>
    <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt; FONT-WEIGHT: bold">Current
Report</font></div>
    <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt; FONT-WEIGHT: bold">Pursuant
to Section 13 or 15(d) of The Securities Exchange Act of 1934</font></div>
    <div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
    <div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
            <td valign="top" width="96%">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt"><font style="FONT-SIZE: 11pt">Date of Report (Date of earliest event
      reported):&#160; <font style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-WEIGHT: bold">February 4,
      2010</font></font></font></div>
            </td>
          </tr></table>
    </div>
    <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt">&#160;</font></div>
    <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
      <hr style="COLOR: black" align="center" noshade size="2" width="16%">&#160;<!--EFPlaceholder-->
 </div>
    <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 16pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Worldwide
Biotech and Pharmaceutical Company</font></div>
    <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt">(Exact
name of registrant as specified in its charter)</font></div>
    <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
      <hr style="COLOR: black" align="center" noshade size="2" width="16%">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
            <td valign="top" width="30%">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Delaware</font></div>
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt">(State
      or other</font></div>
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt">jurisdiction
      of incorporation)</font></div>
            </td>
            <td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt">&#160;
      </font></td>
            <td valign="top" width="30%">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">01-06914</font></div>
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt">(Commission</font></div>
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt">File
      Number)</font></div>
            </td>
            <td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt">&#160;
      </font></td>
            <td valign="top" width="30%">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">59-0950777</font></div>
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt">(I.R.S.
      Employer</font></div>
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt">Identification
      No.)</font></div>
            </td>
          </tr><tr>
            <td align="left" valign="top" width="30%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt">&#160;
      </font></td>
            <td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt">&#160;
      </font></td>
            <td align="left" valign="top" width="30%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt">&#160;
      </font></td>
            <td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt">&#160;
      </font></td>
            <td align="left" valign="top" width="30%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt">&#160;
      </font></td>
          </tr><tr>
            <td colspan="5" valign="top" width="96%">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 4.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt; FONT-WEIGHT: bold">4
      Fenghui South Road, Jie Zuo Mansion,</font></div>
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 4.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt; FONT-WEIGHT: bold">15<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">th</font>
      Floor, A10-11501</font></div>
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 4.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Xi&#8217;an,
      Shaanxi, P. R. China, 710075</font></div>
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 4.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt">(Address
      of principal executive offices)&#160;&#160;(zip code)</font></div>
            </td>
          </tr><tr>
            <td align="left" valign="top" width="30%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt">&#160;
      </font></td>
            <td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt">&#160;
      </font></td>
            <td align="left" valign="top" width="30%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt">&#160;
      </font></td>
            <td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt">&#160;
      </font></td>
            <td align="left" valign="top" width="30%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt">&#160;
      </font></td>
          </tr><tr>
            <td colspan="5" valign="top" width="96%">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 4.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">86-29-88193339</font></div>
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 4.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt">(Registrant&#8217;s
      telephone number, including area code)</font></div>
            </td>
          </tr><tr>
            <td align="left" valign="top" width="30%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt">&#160;
      </font></td>
            <td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt">&#160;
      </font></td>
            <td align="left" valign="top" width="30%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt">&#160;
      </font></td>
            <td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt">&#160;
      </font></td>
            <td align="left" valign="top" width="30%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt">&#160;
      </font></td>
          </tr><tr>
            <td align="left" valign="top" width="30%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt">&#160;
      </font></td>
            <td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt">&#160;
      </font></td>
            <td align="left" valign="top" width="30%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt">________________________________________________</font></td>
            <td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt">&#160;
      </font></td>
            <td align="left" valign="top" width="30%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt">&#160;
      </font></td>
          </tr><tr>
            <td colspan="5" valign="top" width="96%">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 4.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt">&#160;(Former
      name or former address, if changed since last
  report.)</font></div>
            </td>
          </tr></table>
    </div>
    <div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
    <div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
    <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt">Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:</font></div>
    <div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
            <td align="left" valign="top" width="4%">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: wingdings; FONT-SIZE: 11pt">o</font></div>
            </td>
            <td align="left" valign="top" width="92%">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt">Written
      communications pursuant to Rule 425 under the Securities Act (17 CFR
      230.425)</font></div>
            </td>
          </tr></table>
    </div>
    <div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
            <td align="left" valign="top" width="4%">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: wingdings; FONT-SIZE: 11pt">o</font></div>
            </td>
            <td align="left" valign="top" width="92%">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt">Soliciting
      material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)</font></div>
            </td>
          </tr></table>
    </div>
    <div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
            <td align="left" valign="top" width="4%">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: wingdings; FONT-SIZE: 11pt">o</font></div>
            </td>
            <td align="left" valign="top" width="92%">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt">Pre-commencement
      communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
      240.14d-2(b))</font></div>
            </td>
          </tr></table>
    </div>
    <div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
            <td align="left" valign="top" width="4%">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: wingdings; FONT-SIZE: 11pt">o</font></div>
            </td>
            <td align="left" valign="top" width="92%">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt">Pre-commencement
      communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
      240.13e-4(c))</font></div>
            </td>
          </tr></table>
    </div>
    <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div>
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
      <hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
    </div>
    <div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
        </div>
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <hr style="COLOR: darkgray" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt"><font style="FONT-SIZE: 11pt">&#160;</font><a name="FIS_SECTION_4_MATTERS_RELATED_TO_ACCOUNT"><!--EFPlaceholder-->
 </a><a name="FIS_CHANGE_IN_ACCOUNTANT"><!--EFPlaceholder-->
</a></font></div>
    <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt"><font style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-WEIGHT: bold">Item 4.01 Changes in
Registrant&#8217;s Certifying Accountant.</font></font></div>
    <div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
    <div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt">On
February 4, 2010, Worldwide Biotech and Pharmaceutical Company (the
&#8220;Registrant&#8221;) dismissed Kempisty &amp; Company, Certified Public Accountants,
P.C. (&#8220;Kempisty &amp; Company&#8221;) as the Registrant&#8217;s independent registered
public accounting firm.</font></div>
    <div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
    <div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt">For the
year ended December 31, 2008, Kempisty &amp; Company issued an audit report on
the Registrant&#8217;s consolidated balance sheet as of December 31, 2008, and the
related consolidated statements of operations, stockholders&#8217; equity (deficit)
and comprehensive income (loss), and cash flows for the year then ended. The
report of Kempsity &amp; Company on the foregoing financial statements did not
contain any adverse opinion or disclaimer of opinion, nor were they qualified or
modified as to any uncertainty, audit scope or accounting principles, except for
an explanatory paragraph related to the Registrant&#8217;s ability to continue as a
going concern.</font></div>
    <div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
    <div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt">In
addition, Kempisty &amp; Company reviewed management&#8217;s prepared consolidated
financial statements for the Registrant for the quarters ended March 31, 2009,
June 30, 2009 and September 30, 2009.&#160;</font></div>
    <div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
    <div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt">During
the year ended December 31, 2008 and all subsequent interim periods and through
February 4, 2010, (i) there were no disagreements between the Registrant and
Kempisty &amp; Company on any matter of accounting principles or practices,
financial statement disclosure or auditing scope or procedure, which
disagreement(s), if not resolved to the satisfaction of Kempisty &amp; Company
would have caused Kempisty &amp; Company to make reference to the subject matter
of disagreement in connection with its reports on the Registrant&#8217;s financial
statements, and (ii) there were no reportable events as that term is described
in Item 304(a)(1)(iv) of Regulation S-K. &#160;</font></div>
    <div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
    <div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt">On
February 4, 2010, we engaged Yichien Yeh, CPA (&#8220;Yeh&#8221;) as the Registrant&#8217;s new
independent registered public accounting firm. The Registrant&#8217;s Board of
Directors recommended, authorized, and approved the decision to dismiss Kempisty
&amp; Company as our independent registered public accounting firm and to engage
Yeh to serve as our independent registered public accounting
firm.&#160;</font></div>
    <div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
    <div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt">On
February 26, 2010, we provided Kempisty &amp; Company with a copy of this Form
8-K, and requested that Kempisty &amp; Company furnish us with a letter
addressed to the Securities and Exchange Commission stating whether or not it
agrees with the above statements within ten (10) business days of the filing of
this Form 8-K. We will file an amendment to this Form 8-K within two days of
receipt of Kempisty &amp; Company&#8217;s letter and attach it as an
exhibit.</font></div>
    <div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt; FONT-WEIGHT: bold">&#160;</font></div>
    <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 11pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 11pt; FONT-WEIGHT: bold">Item
5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; </font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 11pt; FONT-WEIGHT: bold">Compensatory
Arrangements of Certain Officers.</font></font></div>
      <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt">&#160;</font></div>
    </div>
    <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 11pt"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;&#160; On
February 22, 2010, Ms. Huimin Zhang resigned from her position as a Director on
the Board of the Registrant and Mr. Xiaohong Bai resigned from his position as
the Vice President of Operations of Yangling Daiying Biotech &amp;
Pharmaceutical Group Co., Ltd., one of the subsidiaries of the Registrant
(&#8220;Yangling Daiying&#8221;).&#160;&#160;On February 23, 2010, Mr. Peiyi Tian resigned
his positions as the Senior Vice President, Chief Financial Officer, Treasurer
and Director of the Registrant.&#160;&#160;All of the aforementioned director
and officers resigned for personal reasons, without any disagreements with the
Registrant, and their resignations were not related to the Registrant&#8217;s
operations, policies or practices. On February 24, 2010, the Board of Directors
of the Registrant accepted the resignations of the Ms. Zhang, Mr. Bai and Mr.
Tian.</font><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt">&#160;&#160;</font></div>
    </div>
    <div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
    <div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt">On
February 24, 2010, the Board of Directors of the Registrant elected Mr. Qiang Li
and Mr. Peng Wang as Directors to replace Ms. Huiming Zhang and Mr. Peiyi
Tian.</font></div>
    <div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
    <div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt">In
addition, on February 24, 2010, the Board of Directors of the Registrant
appointed Mr. Peng Wang to succeed Mr. Peiyi Tian as the Chief Financial Officer
and Treasurer and appointed Mr. Yuan Cheng to replace Mr. Xiaohong Bai as Vice
President of Operations of Yangling Daiying.</font></div>
    <div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
    <div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt">Mr. Qiang
Li, age 34, the Registrant&#8217;s newly-elected director, has 14 years of experience
working extensively in medicine and publishing.&#160;&#160;For the two years
immediately following Mr. Li&#8217;s graduation from Ruicang Health School of Jiangxi
Province in 1994, he worked in Medicare services in the Nancang Taohua Hospital
in Jiangxi Province.&#160;&#160;From 1996 to 2004, Mr. Li was the chief editor
at the Guangdong Branch of the Xinhua News Agency.&#160;&#160;Since 2004, Mr. Li
has been working for Shaanxi Daiying Medicine Distribution Co., Ltd., a
subsidiary of the Registrant.</font></div>
    <div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
    <div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt">Mr. Peng
Wang, age 51, a graduate from Xi&#8217;an University of Finance and Economics, has
worked for over 23 years in finance as a Certified Public
Accountant.&#160;&#160;Prior to Mr. Wang&#8217;s appointment as the Registrant&#8217;s Chief
Financial Officer and Treasurer, he served as a financial officer in
governmental organizations from 1977 to 1995 and as the Chief Financial Officer
of Shaanxi Yuqi Functional Product Factory from 1995 to 2000.</font></div>
    <div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
    <div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt"><font style="FONT-SIZE: 11pt">Mr. Yuan Cheng, age 38, graduated in 1993 from Xi&#8217;An
Medical College with a Bachelors Degree in pharmacy.&#160;&#160;Following his
graduation through 1996, Mr. Cheng worked in the quality control department of
Xi&#8217;An Medical Company.&#160;&#160;From 1996 to 2002, Mr. Cheng was the head of
the production and research and development departments of Nanjing Meirui
Pharmaceutical Co., Ltd.&#160;&#160;Mr. Cheng attended Tianjin University from
2002 to 2006, where he was awarded a Masters Degree in pharmaceutical
engineering.&#160;&#160;After receiving his Masters Degree, Mr. Cheng worked
Shaanxi Haoqijun Pharmaecutical Co., Ltd. until his appointment on February 24,
2010 as Vice President of Operations of Yangling Daiying Biotech &amp;
Pharmaceutial Group Co., Ltd., one of the Registrant&#8217;s subsidiaries.</font><a name="FIS_SIGNATURES"><!--EFPlaceholder-->
 </a></font></div>
    <div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
    <div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">2</font></div>
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <hr style="COLOR: darkgray" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
    <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt; FONT-WEIGHT: bold">SIGNATURES</font></div>
    <div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
    <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.</font></div>
    <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
            <td align="left" valign="top" width="48%">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt">Dated:&#160;&#160;February
      26, 2010</font></div>
            </td>
            <td align="left" valign="top" width="37%">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt">Worldwide
      Biotech and Pharmaceutical Company</font></div>
            </td>
            <td align="left" valign="top" width="11%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt">&#160;
      </font></td>
          </tr><tr>
            <td valign="top" width="48%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt">&#160;
      </font></td>
            <td valign="top" width="37%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt">&#160;
      </font></td>
            <td valign="top" width="11%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt">&#160;
      </font></td>
          </tr><tr>
            <td align="left" valign="top" width="48%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt">&#160;
      </font></td>
            <td align="left" valign="top" width="37%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt">&#160;
      </font></td>
            <td align="left" valign="top" width="11%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt">&#160;
      </font></td>
          </tr><tr>
            <td align="left" valign="top" width="48%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt">&#160;
      </font></td>
            <td align="left" valign="top" width="37%">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt"><font style="TEXT-DECORATION: underline">/s/ Wenxia Guo</font></font></div>
            </td>
            <td align="left" valign="top" width="11%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt">&#160;
      </font></td>
          </tr><tr>
            <td align="left" valign="top" width="48%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt">&#160;
      </font></td>
            <td align="left" valign="top" width="37%">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt">Wenxia
      Guo</font></div>
            </td>
            <td align="left" valign="top" width="11%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt">&#160;
      </font></td>
          </tr><tr>
            <td align="left" valign="top" width="48%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt">&#160;
      </font></td>
            <td align="left" valign="top" width="37%">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt">President
      and Chief Executive Officer&#160;</font></div>
            </td>
            <td align="left" valign="top" width="11%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 11pt">&#160;
      </font></td>
          </tr></table>
    </div>
    <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3</font></div>
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <hr style="COLOR: darkgray" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
  </body>
</html>
[{"type": "8-K", "sequence": "1", "filename": "form8-k.htm", "description": "WWBP 8-K 02/26/2010", "secsgml_size_bytes": 35790}]
{"company-data": {"conformed-name": "Worldwide Biotech & Pharmaceutical CO", "cik": "0000095302", "assigned-sic": "5140", "irs-number": "590950777", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-06914", "film-number": "10640666"}, "business-address": {"street1": "110 SARASOTA QUAY", "city": "SARASOTA", "state": "FL", "zip": "34236", "phone": "941-365-2521"}, "mail-address": {"street1": "110 SARASOTA QUAY", "city": "SARASOTA", "state": "FL", "zip": "34236"}, "former-company": [{"former-conformed-name": "SUN CITY INDUSTRIES INC", "date-changed": "19920703"}, {"former-conformed-name": "SUN CITY DAIRY PRODUCTS INC", "date-changed": "19690727"}]}
form8-k.htm
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C.  20549
Form
8-K
Current
Report
Pursuant
to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event
      reported):
February 4,
      2010
Worldwide
Biotech and Pharmaceutical Company
(Exact
name of registrant as specified in its charter)
Delaware
(State
      or other
jurisdiction
      of incorporation)
01-06914
(Commission
File
      Number)
59-0950777
(I.R.S.
      Employer
Identification
      No.)
4
      Fenghui South Road, Jie Zuo Mansion,
15
th
Floor, A10-11501
Xi'an,
      Shaanxi, P. R. China, 710075
(Address
      of principal executive offices)  (zip code)
86-29-88193339
(Registrant's
      telephone number, including area code)
________________________________________________
(Former
      name or former address, if changed since last
  report.)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o
Written
      communications pursuant to Rule 425 under the Securities Act (17 CFR
      230.425)
o
Soliciting
      material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)
o
Pre-commencement
      communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
      240.14d-2(b))
o
Pre-commencement
      communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
      240.13e-4(c))
Item 4.01 Changes in
Registrant's Certifying Accountant.
On
February 4, 2010, Worldwide Biotech and Pharmaceutical Company (the
"Registrant") dismissed Kempisty & Company, Certified Public Accountants,
P.C. ("Kempisty & Company") as the Registrant's independent registered
public accounting firm.
For the
year ended December 31, 2008, Kempisty & Company issued an audit report on
the Registrant's consolidated balance sheet as of December 31, 2008, and the
related consolidated statements of operations, stockholders' equity (deficit)
and comprehensive income (loss), and cash flows for the year then ended. The
report of Kempsity & Company on the foregoing financial statements did not
contain any adverse opinion or disclaimer of opinion, nor were they qualified or
modified as to any uncertainty, audit scope or accounting principles, except for
an explanatory paragraph related to the Registrant's ability to continue as a
going concern.
In
addition, Kempisty & Company reviewed management's prepared consolidated
financial statements for the Registrant for the quarters ended March 31, 2009,
June 30, 2009 and September 30, 2009.
During
the year ended December 31, 2008 and all subsequent interim periods and through
February 4, 2010, (i) there were no disagreements between the Registrant and
Kempisty & Company on any matter of accounting principles or practices,
financial statement disclosure or auditing scope or procedure, which
disagreement(s), if not resolved to the satisfaction of Kempisty & Company
would have caused Kempisty & Company to make reference to the subject matter
of disagreement in connection with its reports on the Registrant's financial
statements, and (ii) there were no reportable events as that term is described
in Item 304(a)(1)(iv) of Regulation S-K.
On
February 4, 2010, we engaged Yichien Yeh, CPA ("Yeh") as the Registrant's new
independent registered public accounting firm. The Registrant's Board of
Directors recommended, authorized, and approved the decision to dismiss Kempisty
& Company as our independent registered public accounting firm and to engage
Yeh to serve as our independent registered public accounting
firm.
On
February 26, 2010, we provided Kempisty & Company with a copy of this Form
8-K, and requested that Kempisty & Company furnish us with a letter
addressed to the Securities and Exchange Commission stating whether or not it
agrees with the above statements within ten (10) business days of the filing of
this Form 8-K. We will file an amendment to this Form 8-K within two days of
receipt of Kempisty & Company's letter and attach it as an
exhibit.
Item
5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers;
Compensatory
Arrangements of Certain Officers.
On
February 22, 2010, Ms. Huimin Zhang resigned from her position as a Director on
the Board of the Registrant and Mr. Xiaohong Bai resigned from his position as
the Vice President of Operations of Yangling Daiying Biotech &
Pharmaceutical Group Co., Ltd., one of the subsidiaries of the Registrant
("Yangling Daiying").  On February 23, 2010, Mr. Peiyi Tian resigned
his positions as the Senior Vice President, Chief Financial Officer, Treasurer
and Director of the Registrant.  All of the aforementioned director
and officers resigned for personal reasons, without any disagreements with the
Registrant, and their resignations were not related to the Registrant's
operations, policies or practices. On February 24, 2010, the Board of Directors
of the Registrant accepted the resignations of the Ms. Zhang, Mr. Bai and Mr.
Tian.
On
February 24, 2010, the Board of Directors of the Registrant elected Mr. Qiang Li
and Mr. Peng Wang as Directors to replace Ms. Huiming Zhang and Mr. Peiyi
Tian.
In
addition, on February 24, 2010, the Board of Directors of the Registrant
appointed Mr. Peng Wang to succeed Mr. Peiyi Tian as the Chief Financial Officer
and Treasurer and appointed Mr. Yuan Cheng to replace Mr. Xiaohong Bai as Vice
President of Operations of Yangling Daiying.
Mr. Qiang
Li, age 34, the Registrant's newly-elected director, has 14 years of experience
working extensively in medicine and publishing.  For the two years
immediately following Mr. Li's graduation from Ruicang Health School of Jiangxi
Province in 1994, he worked in Medicare services in the Nancang Taohua Hospital
in Jiangxi Province.  From 1996 to 2004, Mr. Li was the chief editor
at the Guangdong Branch of the Xinhua News Agency.  Since 2004, Mr. Li
has been working for Shaanxi Daiying Medicine Distribution Co., Ltd., a
subsidiary of the Registrant.
Mr. Peng
Wang, age 51, a graduate from Xi'an University of Finance and Economics, has
worked for over 23 years in finance as a Certified Public
Accountant.  Prior to Mr. Wang's appointment as the Registrant's Chief
Financial Officer and Treasurer, he served as a financial officer in
governmental organizations from 1977 to 1995 and as the Chief Financial Officer
of Shaanxi Yuqi Functional Product Factory from 1995 to 2000.
Mr. Yuan Cheng, age 38, graduated in 1993 from Xi'An
Medical College with a Bachelors Degree in pharmacy.  Following his
graduation through 1996, Mr. Cheng worked in the quality control department of
Xi'An Medical Company.  From 1996 to 2002, Mr. Cheng was the head of
the production and research and development departments of Nanjing Meirui
Pharmaceutical Co., Ltd.  Mr. Cheng attended Tianjin University from
2002 to 2006, where he was awarded a Masters Degree in pharmaceutical
engineering.  After receiving his Masters Degree, Mr. Cheng worked
Shaanxi Haoqijun Pharmaecutical Co., Ltd. until his appointment on February 24,
2010 as Vice President of Operations of Yangling Daiying Biotech &
Pharmaceutial Group Co., Ltd., one of the Registrant's subsidiaries.
2
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Dated:  February
      26, 2010
Worldwide
      Biotech and Pharmaceutical Company
/s/ Wenxia Guo
Wenxia
      Guo
President
      and Chief Executive Officer
3